Background: Combined non-viral gene therapy (GT) of ischemia and cardiovascular disease is a promising tool for potential clinical translation. In previous studies our group has developed combined gene therapy by vascular endothelial growth factor 165 () + hepatocyte growth factor (). Our recent works have demonstrated that a bicistronic pDNA that carries both human and coding sequences has a potential for clinical application in peripheral artery disease (PAD).
View Article and Find Full Text PDF